Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Malignancy in Chronic Leg Wounds: Diagnostic Delay and Clinical Implications in a Tertiary Wound-Care Cohort.

International wound journal·2026
Same author

Integrated photoprotection and senescence modulation: A topical formulation counteracts cellular aging in human skin cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Lactobacillus-derived extracellular vesicles as postbiotic modulators of redox signalling and cellular senescence in skin homeostasis.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same author

Cutaneous Skin Toxicities of Oncological Targeted Therapies: Comprehensive Overview of Mechanisms, Management, and Research Gaps-A Narrative Review.

Dermatology and therapy·2026
Same author

Toxic Epidermal Necrolysis and Steven-Johnson Syndrome During the Postpartum Period: A Literature Review with a Rare Case Presentation.

Journal of clinical medicine·2026
Same author

Lanadelumab in Hereditary Angioedema: Real-World Outcomes and Implications for Access Practices in Europe.

Journal of clinical medicine·2026

Related Experiment Video

Updated: Apr 28, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

24.5K

LetibotulinumtoxinA for Rosacea: A Pilot Study.

Agnieszka Bańka-Wrona1,2, Witold Wrona2,3, Wioletta Barańska-Rybak4

  • 1Faculty of Medicine, Łazarski University, 02-662 Warsaw, Poland.

Toxins
|April 27, 2026
PubMed
Summary

Intradermal letibotulinumtoxinA shows promise for treating rosacea. This pilot study found it effectively reduced facial redness and flushing, improving skin quality and patient life quality with minimal side effects.

Keywords:
botulinum toxin AletibotulinumtoxinArosacea

More Related Videos

Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application
03:47

Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application

Published on: September 27, 2024

1.6K
Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

1.0K

Related Experiment Videos

Last Updated: Apr 28, 2026

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

24.5K
Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application
03:47

Author Spotlight: Advancing Facial Rejuvenation Therapy with Post-Laser Salicylic Acid Application

Published on: September 27, 2024

1.6K
Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases
07:36

Clinical Application of Intense Pulsed Light Therapy and Radio Frequency for Treatment of Ocular Surface Diseases

Published on: July 3, 2025

1.0K

Area of Science:

  • Dermatology
  • Neurotoxin Research
  • Medical Aesthetics

Background:

  • Rosacea-induced erythema and flushing are often poorly managed by conventional treatments.
  • Intradermal botulinum toxin A is being explored for its potential to address the neurovascular aspects of rosacea.
  • Persistent facial redness and flushing significantly impact patients' quality of life.

Purpose of the Study:

  • To assess the safety and preliminary efficacy of intradermal letibotulinumtoxinA for persistent rosacea erythema and flushing.
  • To evaluate the treatment's impact on skin hydration, sebum, elasticity, and quality of life.

Main Methods:

  • A pilot study involving eleven patients with refractory erythematotelangiectatic rosacea.
  • A single session of intradermal letibotulinumtoxinA (20 U total dose) was administered.
  • Outcomes were assessed at two weeks, including clinician and patient ratings, skin parameters, and Dermatology Life Quality Index (DLQI).

Main Results:

  • 73% of patients experienced improved erythema, and 100% reported reduced flushing.
  • Skin hydration and elasticity increased, while sebum levels decreased.
  • The median DLQI score significantly improved from 9 to 2, indicating enhanced quality of life.

Conclusions:

  • Intradermal letibotulinumtoxinA was well-tolerated with minor, transient side effects.
  • The treatment demonstrated preliminary efficacy in reducing rosacea symptoms and improving skin condition.
  • Larger, controlled studies are needed to confirm these findings for rosacea management.